Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS (NCT00520468), a non-randomized phase 2 study. The primary outcome is Number of Participants With Response.

2. Clinical Question

3. Trial Design

This was a phase 2, non-randomized, single-group study sponsored by M.D. Anderson Cancer Center. It is listed as completed. The registry gives a start date of 2004-06 and a primary completion date of 2009-06. Enrollment was 15. Those details describe the scope and timing of the study, but do not establish the number treated, the number completing follow-up, or the number included in the response assessment. The registry identifies all treated patients on study as the primary analysis population.

Participants received the combined cytokine-immunotherapy regimen: erythropoietin, G-CSF, prednisone and cyclosporin A. There was no random allocation and no masking. The record describes no separate control arm. The design therefore supports a descriptive account of response and reported adverse events among participants receiving the regimen, but it does not provide a randomized estimate of comparative treatment effect. Differences from an external or historical group cannot be interpreted as treatment effects using the information recorded.

The primary objective was to evaluate response rate in low-risk MDS. Secondary objectives were response duration, survival and side effects. The registry record does not report an outcome result for response duration or survival, and the number of response analyses listed is 0. It also does not report a protocol, eligibility criteria in detail, planned recruitment target rationale, treatment discontinuation rules, or follow-up completeness. These omissions limit assessment of how closely the reported record corresponds to the full study plan and how the observed outcomes should be generalized.

Non-randomized single-group studies can describe what happened among treated participants, but they cannot separate a treatment effect from changes that might have occurred without treatment or from differences in participant characteristics. The absence of masking can also matter for outcomes requiring judgment, although the registry identifies formal response categories. The record does not explain whether response classification was independently reviewed or masked. Thus, the design and reporting support a cautious descriptive interpretation rather than a controlled causal conclusion.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Of fifteen patients enrolled, fourteen patients registered were evaluable and one patient taken off study never having received study drug.

Overall Study

Analysis population for the primary outcome, as defined in the registry: All treated patients on study included in analysis.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants With Response, measured over Response evaluation within first 3 months from start of therapy, then every 3 to 6 months.

The primary endpoint is the number of participants with a response. Response was classified using the International Working Group Response Criteria for Myelodysplastic Syndrome. The categories stated in the record are complete remission, partial response, hematologic improvement and no response. The outcome is therefore based on classifying participants’ disease status, rather than on a continuous measurement such as a laboratory value. The registry describes periodic bone marrow samples to check disease-related cells before, during and after the study.

The timing for response evaluation is within the first 3 months from the start of therapy, followed by evaluation every 3 to 6 months. A response endpoint is relevant to the stated primary objective because it records whether participants meet a disease-response classification after receiving the regimen. It can also give a direct count for a single-group study. However, without the number meeting response criteria, the endpoint description alone does not indicate how often response occurred or how precise an estimated response rate would be.

The registry does not report the operational criteria or thresholds used for each category, how missing or unevaluable assessments were handled, or whether response was confirmed. It also does not state which assessment time point determined the primary response classification. The actual number of participants with response is not reported in the registry record. The endpoint definition is therefore available, but the primary result and important details needed to interpret its measurement are not.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical methods help distinguish what an outcome measures from what a study design can establish. In this record, the primary endpoint is a count of participants classified as having a response. The classification uses named response categories, while the underlying assessment includes periodic bone marrow samples. A count can be summarized descriptively, but interpreting it as evidence about a treatment requires attention to the population assessed, the comparison design and the uncertainty around the estimate. The registry describes the endpoint but does not report its response count or an inferential analysis.

What does a response count tell the reader?

A response count records how many participants satisfy a stated response definition in the analysis population. It is different from a comparison of outcomes between treatments. In a single-group study, a response count can describe the experience of those treated, but it does not supply the counterfactual outcome: what would have happened to comparable participants without that regimen or under another regimen. That comparison would require a suitable design and analysis, neither of which is described in this record.

Response categories also require clear operational rules. Complete remission, partial response and hematologic improvement are listed, along with no response, but the specific criteria and thresholds for assigning those classifications are not stated. Assessment timing can influence the classification, especially when participants are assessed repeatedly. The record gives an initial response evaluation within the first 3 months from therapy start, then evaluations every 3 to 6 months, but does not identify which assessment governs the primary outcome or how confirmation and missing assessments were handled.

How should uncertainty be understood?

A confidence interval is a general statistical tool for describing uncertainty around an estimated quantity. It indicates a range of values compatible with the data under the analysis assumptions; it does not remove design limitations or establish causation. For a response proportion, uncertainty depends on the observed outcome information and the analysis population. Since the registry does not report the number with response or a confidence interval, the precision of the primary result cannot be assessed. No interval can be inferred from enrollment alone.

A statistical test, when used, addresses a specified hypothesis under stated assumptions. A p-value is not the probability that a treatment works, nor is it a measure of clinical importance. The registry lists no analyses and gives no p-value or test for the primary endpoint. It also does not report an analysis plan, model, confidence level, covariate adjustment, or approach to hypothesis testing. Accordingly, no claim about statistical significance can be made from the record.

Why does the single-group design matter?

Random allocation is a general method for making treatment groups more comparable, on average, with respect to measured and unmeasured baseline factors. This study was non-randomized and single-group, so there is no randomized treatment contrast in the record. Comparisons with other studies or historical outcomes could be affected by differences in who was enrolled, how outcomes were assessed, and when care was delivered. Such external comparisons are not equivalent to a concurrent randomized control.

Masking can reduce the chance that knowledge of treatment assignment influences outcome assessment or reporting. The record states that masking was none. Formal response criteria may standardize classification, but the record does not say whether assessors were independent or whether assessments were reviewed. The lack of masking is therefore relevant context, not proof that response classification was biased.

What do the planning assumptions mean?

The record includes assumptions for planning illustrations based on an observed effect: a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and an effect expressed as a stated fraction of the observed effect. These are planning assumptions, not a description of this trial’s single-group design. The record does not give the numerical planning outputs or identify a trial-specific sample-size justification. Such illustrations are not observed power and should not be read as evidence that the study had a particular probability of detecting an effect. Sample-size planning describes hypothetical design requirements under assumptions; it does not change the information actually observed.

For binary outcomes, over-dispersion is a general concern when outcomes vary more across groups or settings than a simple model assumes. Accounting for it can affect uncertainty estimates and planning, but the registry does not report a model or over-dispersion adjustment for this endpoint. Since the response analysis and its result are not reported, no model-based calculation can be evaluated. The most defensible reading is to separate documented design details and safety counts from analyses or conclusions that the registry record does not contain.

10. Multiplicity, Missing Data and Analysis Populations

The registry identifies response rate as the primary objective and response duration, survival and side effects as secondary objectives. It lists one primary outcome measure and no analyses. The record does not describe a statistical analysis plan, a hierarchy of hypotheses, or a multiplicity adjustment. When multiple outcomes or repeated hypothesis tests are considered, the chance of a false-positive finding can increase; general methods address that issue by defining which tests are confirmatory and how error rates are controlled. Without a reported plan or analyses, it is not possible to determine how multiplicity was handled or whether any result was intended to be confirmatory.

Missing outcome data can affect both the count and interpretation of a response endpoint. Relevant details include the number assessed at each time, reasons for missing assessments, and rules for classifying participants without an evaluable assessment. The registry describes all treated patients on study as included in the primary analysis, but does not report how many were treated, how many had evaluable response data, or how missing assessments were handled. It therefore does not establish whether the analysis included every treated participant in practice or how incomplete follow-up could affect the result.

The response schedule calls for evaluation within the first 3 months from therapy start and then every 3 to 6 months. The record does not report follow-up completeness, the final assessment time, or a method for handling participants who discontinued or died before an assessment. Response duration and survival are named as secondary objectives, but their results and analysis methods are not reported in the registry record. The distinction between planned objectives and reported analyses is essential: an objective alone does not show that an outcome was analyzed or what the result was.

For safety, the record lists 14 participants at risk, but does not describe missing safety follow-up or the observation window used to identify events. These omissions mean that the completeness of adverse-event ascertainment cannot be evaluated from the registry entry.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: chest pain (28.6%), hemorrhage (21.4%), diarrhea (14.3%), elevated creatinine (14.3%), pain (7.1%).

For the Cytokine-Immunotherapy group, the registry lists 14 participants at risk and 11 affected by serious adverse events. It also lists 14 at risk and 11 affected for other adverse events. The record’s leading serious adverse event terms and reported percentages are chest pain, 28.6%; hemorrhage, 21.4%; diarrhea, 14.3%; elevated creatinine, 14.3%; pain, 7.1%; and fever, 7.1%. These are registry-reported figures and should be read as such, rather than treated as a complete account of every event or its clinical context.

The record does not report the timing, duration, severity grade, treatment attribution, or event-level counts for these terms. It also does not clarify whether a participant could be counted under more than one term. The affected-person counts and term percentages therefore should not be added or interpreted as mutually exclusive categories. The record does not explain why 14 participants are listed as at risk when enrollment was 15. Nor does it describe the safety observation window or how incomplete safety follow-up was handled. These limitations prevent a fuller assessment of the frequency and context of reported events.

12. What the Result Does, and Does Not, Mean

The record establishes that a phase 2 study evaluated a combined cytokine-immunotherapy regimen in low-risk MDS, with response as the primary objective. It specifies the regimen, response categories and assessment schedule. It also records adverse-event figures for participants in the treatment group. These details are useful for understanding what the study set out to assess and how safety information was recorded.

The primary outcome result itself is not reported in the registry record. There is no response count, response estimate, confidence interval or test result to interpret. The registry therefore does not show how frequently participants met the response criteria, how precise a response estimate would be, or whether a particular response category predominated. The description of a response endpoint is not evidence of a response result.

The single-group, non-randomized design also limits what any response result could establish. Even if a response count were available, it would describe outcomes among treated participants rather than provide a randomized comparison with another treatment or a control. The record cannot, by itself, separate a treatment effect from other explanations for observed outcomes. It does not support a causal conclusion about the regimen.

The safety figures describe participants affected and selected adverse-event terms, but the record gives limited context about event timing, severity and attribution. Those figures do not establish that an event was caused by the regimen, and the absence of additional details does not establish that no other events occurred. The record also does not report response duration or survival results, despite listing these as secondary objectives.

In short, the registry record documents a clinical question and a study design, along with selected safety information. It does not contain the primary response result or enough analytical detail to judge its precision. Conclusions about comparative effectiveness, causal effects, or the full safety profile would go beyond what the registry record reports.

13. Why This Trial Matters Statistically

This trial illustrates why endpoint definitions and outcome results must be read separately. The registry provides a named response framework, a set of response categories and an assessment schedule. Those details show what the investigators intended to measure. Yet the number of participants with response is not reported in the registry record. Without the result, a clearly defined endpoint cannot answer the primary clinical question by itself.

It also illustrates the distinction between a treatment description and a treatment comparison. The regimen is described in detail, but the study used a non-randomized single-group design. That structure can provide descriptive information about participants treated under the study conditions. It does not supply a concurrent control outcome or a randomized contrast. Statistical interpretation must follow the design rather than treating a treatment group’s outcome as proof of comparative benefit.

The record also shows why analysis populations and denominators matter. Enrollment was 15, the primary population is described as all treated patients on study, and the safety population is listed as 14 at risk. The registry does not explain how these populations relate. Transparent reporting of who was assessed, who was included in each analysis and how missing data were treated is necessary for readers to evaluate the meaning of counts and percentages.

Finally, the entry distinguishes objectives from reported analyses. Response duration, survival and side effects appear as secondary objectives, but no analyses are listed and the response-duration and survival results are not reported. Statistical literacy includes recognizing that planned aims, defined outcomes and completed analyses are different kinds of information. The record is informative about design and reporting limits, even though it does not provide the primary response result needed to assess the central endpoint.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary limitation for interpreting this study from the registry record is the absence of the primary response result. Although the endpoint, response categories and assessment timing are described, the number of participants with response is not reported. No confidence interval, test result or estimate of precision is listed. The response question therefore remains unanswered by the outcome information in the record.

The non-randomized, single-group design leaves no concurrent control comparison. This limits causal interpretation and makes it impossible to use the record alone to distinguish outcomes associated with treatment from outcomes related to other factors. The registry also states that masking was none; it does not describe independent response review or other steps that might have limited assessment bias.

Several population and follow-up details are absent. Enrollment was 15, while the serious and other adverse-event groups list 14 at risk. The registry does not explain this difference. It also does not provide the number treated, response-assessment completion, loss to follow-up, reasons for missing assessments or rules for handling unevaluable responses. The stated primary population is all treated patients on study, but the record does not provide enough detail to verify how that population was implemented.

The response criteria are named but not fully specified. The record does not state the primary assessment time point, whether response required confirmation, or how response duration and survival were analyzed. It does not report a statistical analysis plan, multiplicity approach, or sample-size justification specific to the trial. Safety reporting lacks event timing, severity grades, attribution and observation-window details. These are limitations of what can be assessed from the registry record, and should not be taken as proof that the full study documentation contains no additional information.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS — NCT00520468.
• Registry record last updated 2012-08-07; status last verified 2012-08.
• Results first posted 2011-04-14.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a completed phase 2, non-randomized, single-group study sponsored by M.D. Anderson Cancer Center, with enrollment of 15 and dates from 2004-06 to 2009-06. The study evaluated erythropoietin, G-CSF, prednisone and cyclosporin A for low-risk MDS. Its primary endpoint was the number of participants with response under International Working Group Response Criteria, assessed within the first 3 months and then every 3 to 6 months. The primary response count is not reported in the registry record. Secondary objectives included response duration, survival and side effects; no analyses are listed. The safety record lists 14 participants at risk and 11 affected for both serious and other adverse events, with selected serious-event terms and percentages. The single-group design, missing primary result and limited analysis details constrain interpretation.